We are live on ! Find out more
PM

Prosight Management Portfolio holdings

AUM $580M
1-Year Est. Return 29.81%
This Fund
S&P 500
This Quarter Est. Return
-1.07%
1 Year Est. Return
+29.81%
3 Year Est. Return
+39.55%
5 Year Est. Return
-6.93%
10 Year Est. Return
–
AUM
$210M
AUM Growth
-$22.7M
Cap. Flow
+$4.13M
Cap. Flow %
1.97%
Top 10 Hldgs %
48.59%
Holding
65
New
13
Increased
16
Reduced
18
Closed
18
Avg Time Held Equity + Options
3 quarters
Top 10 Avg Time Held Equity + Options
1.7 quarters
Top 20 Avg Time Held Equity + Options
3.6 quarters
Avg Time Held Equity only
3.2 quarters
Top 10 Avg Time Held Equity only
1.8 quarters
Top 20 Avg Time Held Equity only
3.7 quarters

Top Buys

Rank Stock Value
1
CUE icon
Cue Biopharma
CUE
+$7.68M
2
AUPH icon
Aurinia Pharmaceuticals
AUPH
+$7.29M
3
BAX icon
Baxter International
BAX
+$6.69M
4
PRTA icon
Prothena Corp
PRTA
+$6.56M
5
MTCR
Metacrine, Inc. Common Stock
MTCR
+$5.31M

Top Sells

Rank Stock Value
1
KURA icon
Kura Oncology
KURA
+$12.8M
2
ARWR icon
Arrowhead Research
ARWR
+$4.93M
3
ARNA
Arena Pharmaceuticals Inc
ARNA
+$4.28M
4
ALDX icon
Aldeyra Therapeutics
ALDX
+$3.41M
5
VCEL icon
Vericel Corp
VCEL
+$2.9M

Sector Composition

Rank Sector Weight
1 Healthcare 92.06%
2 Technology 4.31%
3 Miscellaneous 3.63%
4 Energy 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
KURA icon
26
Kura Oncology
KURA
$874M
$3.29M 1.56%
107,367
-577,633
-84% -$12.8M
2018 Q2
9 quarters
ZGNX
27
DELISTED
Zogenix, Inc.
ZGNX
$3.24M 1.54%
180,924
+34,578
+24% +$847K
2020 Q1
2 quarters
ORGO icon
28
Organogenesis Holdings
ORGO
$156M
$2.6M 1.24%
676,553
+140,937
+26% +$557K
2019 Q4
3 quarters
TVRD icon
29
Tvardi Therapeutics
TVRD
$13.9M
$2.22M 1.06%
4,851
+2,435
+101% +$1.41M
2020 Q2
1 quarter
AMRX icon
30
Amneal Pharmaceuticals
AMRX
$6.82B
$1.99M 0.95%
+512,659
New +$2.19M
2020 Q3
0 quarters
ONEM
31
DELISTED
1Life Healthcare
ONEM
$1.86M 0.89%
+65,778
New +$2.08M
2020 Q3
0 quarters
KZR icon
32
DELISTED
Kezar Life Sciences
KZR
$1.77M 0.84%
+36,598
New +$1.75M
2020 Q3
0 quarters
DNTH icon
33
Dianthus Therapeutics
DNTH
$4.34B
$1.66M 0.79%
15,266
+4,730
+45% +$560K
2020 Q2
1 quarter
QDEL icon
34
QuidelOrtho
QDEL
$967M
$1.65M 0.78%
+7,500
New +$1.67M
2020 Q3
0 quarters
ESTA icon
35
Establishment Labs
ESTA
$1.74B
$1.59M 0.76%
86,042
-41,131
-32% -$732K
2020 Q1
2 quarters
GYRE icon
36
Gyre Therapeutics
GYRE
$711M
$1.3M 0.62%
40,224
+7,151
+22% +$280K
2018 Q3
8 quarters
BTAI icon
37
DELISTED
BioXcel Therapeutics
BTAI
$1.29M 0.61%
+1,863
New +$1.4M
2020 Q3
0 quarters
ADMA icon
38
ADMA Biologics
ADMA
$2.31B
$1.28M 0.61%
535,324
-763,976
-59% -$2.09M
2020 Q1
2 quarters
KRTX icon
39
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$1.22M 0.58%
+15,826
New +$1.35M
2020 Q3
0 quarters
IMTX icon
40
Immatics
IMTX
$1.04B
$1.2M 0.57%
+113,460
New +$1.19M
2020 Q3
0 quarters
NGNE icon
41
Neurogene
NGNE
$431M
$797K 0.38%
+3,319
New +$804K
2020 Q3
0 quarters
EVFM
42
DELISTED
Evofem Biosciences, Inc. Common Stock
EVFM
$590K 0.28%
16,667
-10,852
-39% -$472K
2020 Q2
1 quarter
APEN
43
DELISTED
Apollo Endosurgery, Inc.
APEN
$469K 0.22%
277,590
-102,355
-27% -$154K
2019 Q4
3 quarters
KIDS icon
44
OrthoPediatrics
KIDS
$573M
$386K 0.18%
+8,399
New +$390K
2020 Q3
0 quarters
MITO
45
DELISTED
Stealth BioTherapeutics Corp. ADS
MITO
$346K 0.16%
256,044
-35,100
-12% -$60.1K
2020 Q1
2 quarters
BEAT icon
46
DELISTED
BioTelemetry, Inc.
BEAT
$274K 0.13%
6,000
-18,733
-76% -$783K
2020 Q2
1 quarter
RETA
47
CALL
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
$156K 0.07%
+1,600
New +$200K
2020 Q3
0 quarters
AMN icon
48
AMN Healthcare
AMN
$1.42B
– –
-26,851
Closed -$1.22M –
ARWR icon
49
Arrowhead Research
ARWR
$8.21B
– –
-114,100
Closed -$4.93M –
BMY icon
50
CALL
Bristol-Myers Squibb
BMY
$116B
– –
-50,000
Closed -$2.94M –
1
2
3

Similar funds

SC
Stempoint Capital New York $581M AUM 373.68% 1-Year Est. Return
CCWM
Correct Capital Wealth Management Clayton, Missouri $580M AUM 16.45% 1-Year Est. Return
CMA
Cedar Mountain Advisors Lake Oswego, Oregon $581M AUM 18.16% 1-Year Est. Return
RIS
Retirement Income Solutions Ann Arbor, Michigan $581M AUM 19.42% 1-Year Est. Return
MFS
McNamara Financial Services Marshfield, Massachusetts $580M AUM 17.89% 1-Year Est. Return
GFI
Global Frontier Investments Charleston, South Carolina $581M AUM 8.55% 1-Year Est. Return
PWM
Praetorian Wealth Management Carmel, California $580M AUM 19.43% 1-Year Est. Return
CA
COFG Advisors Oak Brook, Illinois $579M AUM

Prosight Management's Q3 2020 Portfolio in Review

As of Q3 2020, Prosight Management held 65 positions worth $210M, down 9.8% from $233M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Prosight Management's Q3 2020 filing shows 13 new, 16 increased, 18 reduced and 18 closed positions. Its largest new stake was Prothena Corp: 545,195 shares worth $5.45M. The largest sale was Kura Oncology, an estimated $12.8M.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 82% a quarter earlier, followed by Technology and Miscellaneous.

  • Prosight Management's largest Q3 2020 buy was Prothena Corp: 545,195 shares worth $5.45M.
  • Prosight Management added most to Cue Biopharma in Q3 2020, an estimated $7.68M increase.
  • Prosight Management's biggest Q3 2020 reduction was Kura Oncology, cutting an estimated $12.8M.
  • Prosight Management fully exited Arrowhead Research in Q3 2020, selling an estimated $4.93M.
  • Prosight Management's ten largest holdings make up 49% of its $210M portfolio in Q3 2020.
  • Prosight Management opened 13 new positions and closed 18 in Q3 2020.
  • Prosight Management's portfolio value fell 9.8% quarter-over-quarter to $210M.

Based on Prosight Management's 13F filing for Q3 2020, filed 13 Nov 2020.